Literature DB >> 10628900

Rifampicin treatment greatly increases the apparent oral clearance of quinidine.

P Damkier1, L L Hansen, K Brøsen.   

Abstract

We investigated the effect of cytochrome P450 induction by rifampicin on the in vivo oxidative metabolism of quinidine. The pharmacokinetics of a 200 mg oral single dose quinidine were studied before and after one week of daily treatment with 600 mg rifampicin in six healthy young male volunteers. Biomarker reactions of cytochrome P450 isozyme activities in the form of caffeine, sparteine, mephenytoin, tolbutamide and cortisol metabolism were applied. The median total apparent oral clearance and partial clearance by 3-hydroxylation of quinidine increased 9 times. The partial clearance by N-oxidation increased 6 times. The Cmax and the elimination half life were reduced 3 times. No statistically significant changes were found for quinidine tmax and renal clearance. The cortisol metabolic ratio increased 5 times, while no statistically significant effects were seen for other CYP marker reactions. The results indicate that the inductive effect of rifampicin is likely to be of clinical relevance particularly when used concomitantly with drugs metabolized by CYP3A4.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628900     DOI: 10.1111/j.1600-0773.1999.tb02019.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  9 in total

1.  A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Authors:  Michel Tod; S Goutelle; N Bleyzac; L Bourguignon
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

2.  Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria.

Authors:  S Pukrittayakamee; S Prakongpan; S Wanwimolruk; R Clemens; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 3.  CYP induction-mediated drug interactions: in vitro assessment and clinical implications.

Authors:  Jiunn H Lin
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

4.  Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.

Authors:  Ryuta Asaumi; Ken-Ichi Nunoya; Yoshiyuki Yamaura; Kunal S Taskar; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-06

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

7.  Characterization of the mechanism of drug-drug interactions from PubMed using MeSH terms.

Authors:  Yin Lu; Bryan Figler; Hong Huang; Yi-Cheng Tu; Ju Wang; Feng Cheng
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

8.  Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.

Authors:  Shinji Yamazaki; Chester Costales; Sarah Lazzaro; Soraya Eatemadpour; Emi Kimoto; Manthena V Varma
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-09-05

9.  Interaction between rifampicin, amodiaquine and artemether in mice infected with chloroquine resistant Plasmodium berghei.

Authors:  Joseph A Badejo; Oyindamola O Abiodun; Olugbenga Akinola; Christian T Happi; Akintunde Sowunmi; Grace O Gbotosho
Journal:  Malar J       Date:  2014-08-05       Impact factor: 2.979

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.